Protean BioDiagnostics Presents Poster at AACR 2021 Annual Meeting

April 12, 2021 10:00 AM

Innovative OncoSignal technology enables rapid measurement of key oncogenic signaling pathways for targeted breast cancer treatment ORLANDO, FL / ACCESSWIRE / April 12, 2021 / Protean BioDiagnostics Inc. ("Protean"), a disruptive biotechnology company developing and commercializing novel cancer diagnostics supporting precision oncology, today announced that Dr. Anthony Magliocco, President and CEO of Protean, presented a poster at...

Read more

Philogen Announces Publication of the Construction and Application of an Innovative DNA-Encoded Chemical Library in Nature Chemistry

April 12, 2021 8:45 AM

(i) Study shows the generation of a high-quality stereo- and regiodefined DNA-encoded chemical library - (ii) Identified ligands against tumor-associated antigens can serve as vehicles for pharmacodelivery applications SIENA, ITALY / ACCESSWIRE / April 12, 2021 / Philogen S.p.A., a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor-targeting antibodies and small molecule ligands, is...

Read more

Philogen Announces Participation to the 10th World Congress of Melanoma

April 12, 2021 8:45 AM

(i) Philogen will give a poster presentation about the phase II study of Daromun (Nidlegy) for the treatment of non-melanoma skin cancer - (ii) Study shows promising early signs of efficacy in patients with basal cell carcinoma SIENA, ITALY / ACCESSWIRE / April 12, 2021 / Philogen S.p.A., a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor-targeting antibodies and small molecule...

Read more

Applied UV Receives Patent for Pathogen Destroying Devices in China

April 12, 2021 8:30 AM

Adds to Company's Portfolio of Patents for Disinfection Technology Addressing Global Challenge of Controlling the Spread of Emerging Pathogens MOUNT VERNON, NY / ACCESSWIRE / April 12, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion...

Read more

ANGLE's Parsortix system showcased at AACR 2021

April 12, 2021 2:00 AM

ANGLE'S PARSORTIX SYSTEM SHOWCASED IN POSTER PRESENTATIONS AT LEADING CANCER CONFERENCE Publication of study results demonstrating the capabilities of two new assays in clinical samples at AACR 2021 Immunotherapy assay enables determination of PD-L1 status in significant proportion of patients and could guide personalised treatment selection GUILDFORD, SURREY / ACCESSWIRE / April 12, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a...

Read more

Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at 2021 AACR Annual Meeting

April 10, 2021 2:15 PM

Additional, ongoing confirmed durable partial response and three additional patients with stable disease as best response at the highest dose cohort of cinrebafusp alfa Durable anti-tumor activity in heavily pre-treated patient population ​including "cold" and HER2-low expressing tumors Dose-dependent immune activation and 4-1BB modulation in both HER2-high and HER2-low expressing patients PRS-344/S095012 preclinical data...

Read more

Molecular Partners Shares New Preclinical Data from its AML-Focused CD3 T-Cell Engager Program, CD40 Product Candidate MP0317, and Other Novel Immuno-oncology Approaches at AACR

April 10, 2021 8:30 AM

Data support potential of DARPin® CD3 T-cell engager candidate for improved safety window while limiting tumor escape New data show that the FAP x CD40 product candidate, MP0317, led to a localized macrophage repolarization and reversion of T-cell suppression. Clinical trials expected to initiate in the second half of 2021 Effector control technologies give new potential for enhancing current and future immunotherapies while reducing...

Read more

Helix BioPharma Corp. Extends Period to Exercise Warrants

April 9, 2021 5:00 PM

RICHMOND HILL, ON / ACCESSWIRE / April 9, 2021 / Helix BioPharma Corp. (TSX:HBP)(FSE:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received conditional approval from the Toronto Stock Exchange (the "TSX") to extend the exercise period of a total of 2,837,000 outstanding common share...

Read more

Wuhan General Group Introduces Liviana(TM) CBD Infused Artisanal Olive Oil

April 9, 2021 11:25 AM

CAPE TOWN, SA / ACCESSWIRE / April 9, 2021 / WUHAN GENERAL GROUP, INC. (OTC:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update regarding its latest brand offering: We are thrilled to introduce our upcoming brand LivianaTM which is set to launch in May 2021. The LivianaTM brand will kick off its...

Read more

EV Biologics Confirms Funding to Commence Cell Line Generation & Advance Exosome Research

April 8, 2021 9:30 AM

NASHVILLE, TN / ACCESSWIRE / April 8, 2021 / EV Biologics Corp (OTC PINK:YECO) today announced that it has signed a director's loan agreement to secure funding of up to $5 million to start generation of a novel exosome-producer cell line and production of therapeutic exosomes for preclinical research. The Company has finalized its preparation and is ready to begin generation of a novel exosome-producer master cell bank to enable...

Read more

Havn Life Completes Acquisition of Strategic Manufacturing & Packaging Facility for its Retail Division

April 8, 2021 8:00 AM

The Facility acquisition positions Havn Life to quickly expand its product portfolio and reach additional NHP categories. VANCOUVER, BC / ACCESSWIRE / April 8, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce, further...

Read more

Integrated BioPharma Announces Launch of Investors Website

April 8, 2021 8:00 AM

Integrated BioPharma Announces Launch of Investors Website HILLSIDE, NJ / ACCESSWIRE / April 8, 2021 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") announces the launch of an updated investors website. "As part of our efforts in supporting Integrated BioPharma, Inc. and its shareholders in the public markets, we are excited to announce, that effective today, INBP has launched an updated...

Read more

Oncology Pharma Signs License Agreement for mRNA Intellectual Property As It Reveals Strategic Plans for Treating Pancreatic Cancer

April 7, 2021 3:30 PM

SAN FRANCISCO, CA / ACCESSWIRE / April 7, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) signed a license agreement with Regen BioPharma Inc. for intellectual property pertaining to mRNA to be used in developing a therapy for treating pancreatic cancer. This license agreement expands the Company's portfolio of intellectual property that It plans to develop for niche biotechnology markets. Oncology Pharma issued a statement "We are...

Read more

First U.S. Patent Issues on Hancock Jaffe VenoValve

April 7, 2021 1:40 PM

IRVINE, CA / ACCESSWIRE / April 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the United States Patent and Trademark Office (USPTO) has issued the first patent covering the company's VenoValve. The patent is entitled Implantable Vein Frame and is U.S. patent number 10,959,841. The company recently announced that only twenty-eight (28)...

Read more

CELFULL Celebrates its 20th Anniversary with a New Journey on the Way

April 7, 2021 9:30 AM

The anti-aging company CELFULL was founded in 2001 and will celebrate its 20th anniversary on April 18, 2021. CORAL SPRINGS, FL / ACCESSWIRE / April 7, 2021 / CELFULL is a brand of Puressence Biotech (USA) Inc. and dates back to 2001.The theme of the company's 20th anniversary is "Make a difference with your life". The anniversary slogan is based on the company's slogan "Restore Life Vitality". The company looks...

Read more

Chattahoochee Labs/HeliosDx Announces Record Setting First Quarter

April 7, 2021 8:00 AM

ALPHARETTA, GA / ACCESSWIRE / April 7, 2021 / RushNet, Inc. (OTC PINK:RSHN), ("the Company") recently acquired and D/B/A Chattahoochee Labs/HeliosDx, is pleased to announce a record-setting first quarter with total revenues of $1,252,000. The first quarter proved challenging on many fronts. As previously noted, we expanded our testing capacity, as well as our testing capabilities. This process commenced in Q4 2020, but the bulk of...

Read more

Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells(R) to Treat COVID-19

April 6, 2021 1:45 PM

GOLDEN, CO / ACCESSWIRE / April 6, 2021 / Vitro Biopharma, Inc. announced receipt of FDA authorization and clearance to enroll patients in its phase I-2a, randomized, double-blinded, placebo-controlled study of the safety and efficacy of therapeutic treatment with AlloRx Stem Cells® in adults with COVID-19. Our Investigational New Drug (IND) application will investigate the clinical effects of AlloRx Stem Cells® by studying safety and...

Read more

Capstone Therapeutics Corp. Announces Transaction with Diamond Products Holdings, LLC

April 6, 2021 12:30 PM

Capstone Subsidiary Issues Debt to Acquire Equity Interest in Operating Company ALSIP, IL / ACCESSWIRE / April 6, 2021 / On March 31, 2021, the Company, through its relationship with Brookstone Partners (New York), executed definitive documents and acquired a minority interest in a consumer products company, Diamond Products, LLC ("Diamond"), a sexual wellness holding company. The transaction is based on the following...

Read more

Viewpoint Molecular Targeting(TM) Announces Strategic Partnership with Eichrom Technologies to Accelerate Isotope Production Process Development

April 6, 2021 10:00 AM

Automation of Manufacturing Is Critical to Scaling Viewpoint’s Isotope Production Technologies in a Way That Is Safe for Personnel and Cost Effective CORALVILLE, IA / ACCESSWIRE / April 6, 2021 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced...

Read more

Lexaria to Evaluate DehydraTECH(TM) in Multiple New Markets

April 6, 2021 7:05 AM

Undertaking new 2021 R&D programs in additional drug markets with combined market potential of $87 Billion. KELOWNA, BC / ACCESSWIRE / April 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, will begin important new applied research and development (R&D) study programs planned in 2021. Lexaria's new study...

Read more